Amikacin Sulfate

硫酸阿米卡星

Report date: 2026/05/23 20:00:57
NMEQIDP

Base Information

Drug NameAmikacin Sulfate
Drug Alias NameAmikacin Inhale阿米卡星硫酸盐硫酸阿米卡霉素硫酸丁胺卡那霉素阿米卡星 +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Action30S ribosomal subunit inhibitors
Targets30S ribosomal subunit
Therapy Area/IndicationsMultiple SclerosisBronchiectasisCystic Fibrosis +[9] 
Global Approved IndicationsMultiple SclerosisBacterial Infections
Approved Indications in ChinaBacterial Infections
Original Approved Country/TerritoryMainland China
Original Approved Date1981/01/01
Country/TerritoryCzechiaBelgiumBulgaria +[35] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesNipro CorpInsmed IncHuazhong Pharmaceutical Co Ltd
Inactive CompaniesBayer Pharma AgUniversity Medical Center GroningenNektar Therapeutics +[6] 
Active IndicationsMultiple SclerosisBacterial Infections
Inactive IndicationsBronchiectasisCystic FibrosisPneumonia +[7] 

Other Information

ATC CodeD06AX12J01GB06S01AA21
Related LinksN/A